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Abstract. The aim of the present study was to evaluate by
immunohistochemistry the prognostic meaning of the tumor
marker MET (hepatocyte growth factor) in patients submitted
to surgical resection due to primary colorectal adenocarcinoma.
Patients and Methods: A retrospective study was carried out
that included 286 consecutive patients with colorectal adeno-
carcinoma, submitted to surgical resection at Barretos Cancer
Hospital, from 1993 to 2002. The histopathological expression
of the MET tumor marker was evaluated using an anti-protein
monoclonal antibody against MET by the streptavidin-biotin-
peroxidase technique. The expression of the tumor marker was
semi-quantitative, and the slide samples were independently
analyzed by three pathologists unaware of patient clinical and
histopathological data. Results: The tumor marker expression
was positive in 236 (79%) out of a total of 286 patients. This
expression was statistically significantly different between stages
I and IV (p=0.004), for overall survival (p=0.009), and for
cancer-related mortality rates (p=0.022). However, no
association between the tumor marker and recurrence (p=0.89)
or disease-free interval (p=0.91) was observed. Conclusion:
MET has shown significant expression at advanced stages of
the disease, as well as for overall survival and cancer-related
mortality rates demonstrating to be a valuable marker for poor
prognosis in colorectal cancer patients.
Colorectal cancer is the most important cause of cancer dead
among gastrointestinal cancer patients (1). In the United
States of America, 106,680 new colorectal cancer cases were
expected for 2006 and 41,930 cases of rectal cancer (2).
Similarly in Brazil, colorectal cancer is one of the five more
prevalent types of cancer among women and men, mainly in
individuals 50 to 70 years old (3).
Several clinical, pathological and epidemiological factors
can influence the patient’s prognosis (4, 5) but the classification
of tumor stage is the most significant parameter used to
evaluate clinical behavior. Consequently, the presence of lymph
node metastasis indicates that only 30% of patients survive for
five years, and for those with hepatic metastasis, life
expectancy is severely limited. However, tumor stage alone is
far from comprehensive in terms of prognosis which seriously
limits its use for this purpose. Theoretically, patients staged I or
II should demonstrate good prognosis; however, one third of
these patients die in five years with distant metastasis or local
relapse (6). Conversely, there are patients with very
voluminous tumoral masses involving contiguous tissues and
organs without lymph node invasion or distant metastasis, and
benevolent clinical behavior (7-10). Consequently, it is crucial
to find one or more parameters informative for prognosis.
Among a plethora of tumoral markers, the activity of
mesenchymal-epithelial transition factor, a proto-oncogene
that encodes a protein MET, known as MET hepatocyte
growth factor receptor (HGFR), is believed to be particularly
important in cancer prognosis. HGF is the unique ligand
known for MET which is involved in carcinogenesis of
several types of tumors, invasion, differentiation and tumoral
angiogenesis (11-19). Perceptibly, the expression of MET
protein is believed to be crucial to determine prognosis. It has
already been demonstrated that MET can enhance colorectal
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tumoral cell motility, facilitating invasion and metastasis (13).
Interestingly, HGF is not detectable in normal hepatic cells
but its expression is enhanced in hepatocytes neighboring the
malignant colorectal tumor cells metastasized to the liver
(20). High expression of MET in malignant transformation is
also associated with an augmented capacity for invasion and
metastasis (21). In fact, MET was reported to be expressed in
more than 50% of colorectal lesions from dysplastic adenoma
to invasive carcinoma, which suggests that MET influence
occurs from the early stages of malignant disease and is
highly associated with advanced disease (22). Despite its the
well-documented role in the metastatic potential of colorectal
cancer (23), MET did not demonstrate any independent value
as a prognostic factor (17). Indeed, the alleged participation
of MET amplification in colorectal cancer development is not
unequivocal (24), but the majority of investigations have
reported data supporting the participation of MET in
colorectal cancer. Increased MET expression is frequently
associated with concomitant augmentation of HGF
expression, which infers a paracrine effect that optimizes the
cellular mass expansion (18). Moreover MET/HGF is more
significantly expressed in Dukes’ C than Dukes’ B tumors.
Both conditions are limited to the organ but differ in lymph
node status, which infers that MET/HGF expression can
predict metastasis (11).
The aim of this work was to verify if HGFR was more
highly expressed or not in advanced stages of colorectal cancer
and to correlate these findings with prognosis and mortality.
Patients and Methods
All 286 patients enrolled in this study were consecutively examined
and treated by surgery at Barretos Cancer Hospital, in São Paulo
State, Brazil, between 1993 and 2002 due to colorectal
adenocarcinoma. Clinical and pathological data were retrospectively
obtained from the files of the hospital medical archive. Cases with
history of any previous cancer treatment were excluded. General
information included size of the tumor, histological classification of
the tumor, including type and degree of histopathological
differentiation, invasion of colonic wall, lymph node invasion and
distant metastasis, time to recurrence, survival rates and cause of
death when death occurred.
Immunohistochemistry reaction. Immunohistochemistry was
performed according to the avidin–biotin–peroxidase complex
principle (Dako Co., San Diego, CA, USA), using a primary
antibody raised against MET oncoprotein (HGTR), NCL-MET
(Dako Co.) diluted at 1:1500. 
Briefly, deparaffinized and rehydrated sections were immersed in
EDTA (pH 8.0), heated to 98˚C in a water-bath for 15 minutes and
washed in phosphate-buffered saline (PBS). Endogenous
peroxidases were then inactivated using 3% hydrogen peroxide in
methanol for 10 minutes, followed by washing in PBS. Tissue
sections were then incubated with blocking solution for 10 minutes
and incubated at room temperature with the primary antibody for 2
hours. Sections were then sequentially washed in PBS and incubated
with biotinylated goat anti-polyvalent antibody for 10 minutes,
streptavidin peroxidase for 10 minutes, and developed with 3,3’-
diaminobenzidine (DAB+ Substrate System; Dako, Carpinteria, CA,
USA) for 10 minutes. Tissue sections were counterstained with
hematoxylin and permanently mounted.
Immunohistochemical evaluation. The immunoreaction was scored
semi-quantitatively according to Wielenga et al. (25): the reactions
were considered augmented when ≥50% of the malignant cells were
positively stained; (Figure 1) and diminished when the positive cells
were between >10% to <50% (Figure 2). Cases were considered
negative for MET when ≤10% of cells gave positive reactions
(Figure 3).
Evaluation of MET immunohistochemical expression was
performed blindly by two independent observers and discordant
results were reassessed using in a double-head microscope and a
final score was agreed.
Statistical analysis. Data were stored and analyzed using SPSS
statistical software (version 14.0; SPSS Inc., Chicago, IL, USA).
The comparison of MET expression between tumor and normal
cells, as well as the relationship between MET expressions and the
clinicopathological parameters, were examined for statistical
significance using Pearson’s chi-square (χ2) test, using a threshold
for significance of p-values <0.05. Survival curves were plotted
using the method of Kaplan and Meier and data compared using the
log-rank test.
Ethics. The study was approved by the local Committees of Ethics
on Research (No. 0436/04).
Results
A total of 286 patients were enrolled in the study, with mean
age of 63 years (ranged from 28 to 93): 154 (50.3%) male
and 142 (49.7%) female. Adenocarcinoma without other
specification was the predominant histopathological type with
251 (88%) cases, followed by 24 (8%) mucinous type, 9 (3%)
tubular type and 2 (1%) squamous adenocarcinoma. In 210
cases (73%), the colonic wall had been invaded and the tumor
reached the serosal membrane or adjacent structures (T4); in
43 (15%), the tumor had invaded the subserosal zone (T3);
in 28 (9%) the muscular propria, and in 5 (2%) cases the
tumor was restricted to the submucosal (T1). There were 195
(68%) cases exhibiting lymph node invasion and 91 (32%)
cases without lymph node invasion. Distant metastases were
not observed in 217 patients (76%) at first examination and
69 (24%) patients already showed signs of metastatic disease.
TNM classification showed 40 (14%) stage I, 110 (39%)
stage II; 67 (23%) stage III and 69 (24%) stage IV tumors. 
MET reaction was positive in 236 (79%) and negative in
50 (21%) cases. The expression of MET according tumor
stage is depicted in Table I. A statistically significant
difference (p=0.004) in MET expression between stages was
observed, with stage IV associated with augmented and stage
I with diminished MET expression. Table II shows the
comparison between MET expression and recurrence. Stage
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IV patients and patients lost from follow-up were excluded
from this analysis, but no significant difference was found.
Figure 4a shows the Kaplan-Meier survival curves and by
log-rank test, no statistical difference was observed among
the three groups (p=0.96), which implies that the disease-
free interval is not associated with MET expression. 
Figure 4b shows the curve of general survival rates
according to MET expression. Interestingly, longer survival
rates (p=0.009) were observed for the MET diminished
group. The overall correlation of MET and mortality is given
in Table III, which shows that 49.3% of the patients with
augmented expression of MET were dead by the end of this
study, whilst the majority of the MET-negative group were
not (χ2=14.82; p=0.022).
Discussion
We sought to investigate MET expression as a possible tool to
indicate better or worse prognosis in cases of colorectal cancer.
As previously mentioned there is a progressive augmentation of
MET expression in the early stages of adenoma/carcinoma
transformation, but this pattern is not useful for predicting
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Figure 1. Highly augmented MET expression (×100).
Figure 4. Recurrence-free (a) and overall (b) survival according to MET
expression. DE, Diminished expression; AE, augmented expression.
Log-rank test a, p=0.96; b, p=0.009.
Figure 2. Diminished MET expression (×100).
Figure 3. Negative case, without MET expression (×100).
recurrence or the disease-free interval. For this reason, TNM
classification is still believed to be a better option in evaluating
prognosis. However, we observed that MET was proportionally
less expressed in incipient carcinomas than in advanced stages
of colorectal cancer. Our data are in part corroborated by some
data already published where MET was indeed demonstrated to
be a good marker for predicting the metastatic potential of
colorectal tumors (11, 26). Despite its utility in demonstrating
tumor aggressiveness, there was no valid indication for any
association between MET expression and survival rates (27).
Conversely, the data obtained herein significantly demonstrated
that the patients with diminished expression of MET had greater
survival rates when compared with the group of patients with
high expression of MET, which endorses the basis of our study
that highly expressed MET is more commonly related to worse
prognosis; however, this assumption is not consensual (27).
Moreover, we found that MET correlated to TNM stages with a
perceptible and progressive increase of MET expression from
stage I to stage IV (22, 23, 26). Additionally, we opted for
immunohistochemical evaluation of MET because this method
is reproducible and easily applicable in routine of pathology. 
Despite controversies, we demonstrate that immunohisto-
chemical expression of MET is useful in colorectal cancer
prognostic evaluation.
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